Integrated Filing — IndAS



General information about company

Scrip Code 532523
NSE Symbol BIOCON
MSEI Symbol NOTLISTED
ISIN INE376G01013
Name of company BIOCON LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 11-11-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 06-10-2025
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Pharmaceutical
Start date and time of board meeting 11-11-2025   16:30:00
End date and time of board meeting 11-11-2025   17:45:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 30-01-2025
Indicate Company website link for updated RPT policy of the Company https://www.biocon.com/docs/Policy-on-Related-Party-Transactions.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
No default on Loans and Debt Securities



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 58,330.00 1,12,040.00
Other income 13,380.00 19,510.00
Total income 71,710.00 1,31,550.00
2 Expenses
(a) Cost of materials consumed 32,070.00 60,870.00
(b) Purchases of stock-in-trade 2,410.00 4,520.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (7,840.00) (13,270.00)
(d) Employee benefit expense 12,620.00 25,190.00
(e) Finance costs 6,720.00 12,340.00
(f) Depreciation, depletion and amortisation expense 3,380.00 6,710.00
(f) Other Expenses
1 Other Expenses 13,780.00 27,440.00
2 Recovery of cost from co-development partners (net) 0.00 (60.00)
Total other expenses 13,780.00 27,380.00
Total expenses 63,140.00 1,23,740.00
3 Total profit before exceptional items and tax 8,570.00 7,810.00
4 Exceptional items 0.00 0.00
5 Total profit before tax 8,570.00 7,810.00
6 Tax expense
7 Current tax 320.00 430.00
8 Deferred tax 1,160.00 1,120.00
9 Total tax expenses 1,480.00 1,550.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 7,090.00 6,260.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 7,090.00 6,260.00
17 Other comprehensive income net of taxes 90.00 (570.00)
18 Total Comprehensive Income for the period 7,180.00 5,690.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 66,850.00 66,850.00
Face value of equity share capital 5 5
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 0.55 0.49
Diluted earnings (loss) per share from continuing operations 0.55 0.48
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 0.55 0.49
Diluted earnings (loss) per share from continuing and discontinued operations 0.55 0.48
24 Debt equity ratio 0.00 0.00
25 Debt service coverage ratio 0.00 0.00
26 Interest service coverage ratio 0.00 0.00
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 in respect of Biocon Limited (‘the Company’) have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on November 11, 2025. The above results have been subjected to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified. 2. These financial results have been prepared in accordance with Indian Accounting Standards (‘Ind AS’) prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 3. The consolidated financial results include the financial results of the Company and its subsidiaries as follows: i. Syngene International Limited (‘’Syngene’’) ii. Biocon Biologics Limited (“BBL”) iii. Biocon Pharma Limited (“BPL”) iv. Biocon Academy v. Biocon SA vi. Biocon SDN. BHD vii. Biocon FZ LLC viii. Biocon Biologics International Limited (formerly known as Biocon Biologics UK Limited) ix. Biocon Pharma Inc. x. Biocon Biologics Healthcare Malaysia SDN. BHD xi. Biocon Pharma Ireland Limited xii. Biocon Pharma UK Limited xiii. Biocon Biosphere Limited xiv. Biocon Biologics Inc. xv. Biocon Biologics Do Brasil Ltda xvi. Biocon Biologics FZ-LLC xvii. Biocon Pharma Malta Limited xviii. Biocon Pharma Malta I Limited xix. Syngene USA Inc. xx. Syngene Manufacturing Solutions Limited xxi. Syngene Scientific Solutions Limited xxii. Biosimilar Collaborations Ireland Limited xxiii. Biocon Biologics UK PLC (formerly known as Biosimilars Newco Limited) xxiv. Biocon Biologics Canada Inc. xxv. Biocon Biologics Germany GmbH xxvi. Biocon Biologics France S.A.S xxvii. Biocon Biologics Spain, S.L. xxviii. Biocon Biologics Switzerland AG xxix. Biocon Biologics Belgium BV xxx. Biocon Biologics Finland OY xxxi. Biocon Generics Inc. xxxii. Biocon Biologics Morocco S.A.R.L.A.U xxxiii. Biocon Biologics Greece SINGLE MEMBER P.C xxxiv. Biocon Biologics South Africa (PTY) Ltd xxxv. Biocon Biologics (Thailand) Co. Ltd xxxvi. Biocon Biologics Philippines Inc xxxvii. Biocon Biologics Italy S.R.L xxxviii. Biocon Biologics Croatia LLC xxxix. Biocon Biologics Global PLC Biocon Limited and its subsidiaries are collectively referred to as ‘the Group’. In addition to the above, the consolidated financial results also include the financial results in respect of Biocon India Limited Employee Welfare Trust, Biocon Limited Employees Welfare Trust, Biocon Biologics Employees Welfare Trust and Syngene Employees Welfare Trust. The Company has also accounted for its share of interest in the joint venture i.e. NeoBiocon FZ-LLC (‘JV’) and share of investment in the associate i.e. Iatrica Inc., under the equity method. 4. During the quarter ended June 30, 2025, the Company raised funds by way of allotment of 136,363,635 Equity Shares of face value Rs. 5 each at a price of Rs. 330 per Equity Share under ‘Qualified Institutional Placement’ for an aggregate amount of Rs. 45,000 million, to meet certain financial commitments and / or debt obligations of the Company and its subsidiary, BBL and/ or for other purposes as mentioned in the Placement Document (‘PD’). Out of the above proceeds, on June 30, 2025, the Company acquired 1,125 outstanding Optionally Convertible Debentures (‘OCDs’) issued by BBL from Goldman Sachs India AIF Scheme- 1 and Goldman Sachs India Alternative Investment Trust AIF Scheme – 2 for an aggregate value of Rs. 16,980 million with a right to convert into equity shares or redeem at maturity. Further the company has issued a commitment letter effective July 1, 2025, committing to exercise its right to convert OCDs on maturity as per the terms of Subscription Agreement. Out of the above proceeds, during the quarter ended September 30, 2025, the Company has settled Commercial paper for an aggregate value of Rs. 5,988 million. 5. On April 23, 2025, the Board of Directors of Syngene recommended a final dividend of Rs. 1.25 per equity share of Rs. 10/-. This was approved by the shareholders of Syngene in the Annual General Meeting dated July 23, 2025, and has been distributed to the shareholders of Syngene during the quarter and half year ended September 30, 2025. 6. On May 08, 2025, the Board of Directors of the Company recommended a final dividend of Rs. 0.50 per equity share of Rs. 5/- each. This was approved by the shareholders of Company in the Annual General Meeting dated August 08, 2025, and has been distributed to the shareholders of the Company during the quarter and half year ended September 30, 2025. 7. In April 2024, BBL sold to Eris Lifesciences (‘Eris’) its business in relation to Metabolics, Oncology, and Critical Care products in India for a consideration of Rs. 12,420 million. Further, BBL signed a 10 year supply agreement with Eris. This resulted in a gain of Rs. 10,573 million after taking into account working capital and expenses incurred towards commercial collaboration and the same is disclosed under ‘’Other income” in the consolidated financial results for the year ended March 31, 2025. 8. Pursuant to amendment in The Finance Act, 2024, resulting in withdrawal of indexation benefit on Long-Term Capital Gain, the Company has written off Deferred Tax Asset created towards indexation benefit on Land amounting to Rs. 199 million. This is recorded under ‘Tax expense’ in the standalone and consolidated financial results for the quarter ended September 30, 2024 and year ended March 31, 2025. 9. The Group considers estimated shelf life of products, planned product discontinuances, price changes, ageing of inventory and introduction of competitive new products, to the extent each of these factors impact the Group’s business and markets, in determining the provision for slow moving, obsolete and other non-saleable inventory. Pursuant to the take-over of the Viatris's biosimilar business and completion of first anniversary since the exit from the transition service agreement, BBL re-assessed the provision for inventory of finished goods, raw material and semi-finished goods. This assessment resulted into a release of provision of Rs. 650 million in the year ended March 31, 2025 and the credit has been accounted for as a change in estimate within ‘Changes in inventories of traded goods, finished goods and work-in-progress’ and ‘Cost of materials consumed’ in the consolidated financial results. 10. During the year ended 31 March 2025, Syngene USA Inc. (wholly-owned subsidiary of Syngene) acquired biologics site in the USA fitted with multiple monoclonal antibody (mAbs) manufacturing lines from Emergent Manufacturing Operations Baltimore, LLC (a subsidiary of Emergent BioSolutions Inc.) and accounted for this transaction as an 'asset acquisition' under Ind AS 103. The costs incurred till March 31, 2025 eligible for capitalization were accumulated as Capital Work In Progress amounting to Rs. 2,981 million. An amount of Rs. 311 million has been capitalized as Land. These amounts include pre-transaction costs of Rs. 101 million. During the quarter and half year ended September 30 2025, additional pre-operating cost of Rs. 110 million and Rs. 165 million respectively, eligible for capitalisation has been accumulated under capital work in progress. 11. During the quarter and half year ended September 30, 2025, Syngene has written off Rs. 277 million as unrecoverable balances in receivables due to cumulative changes in foreign exchange rates. Consequent tax impact of Rs. 75 million is included within tax expense for the period. 12. During the quarter ended June 30, 2025, Syngene has been granted license for one of the drug substance production line and bonded warehouse license at biologics manufacturing facility, Bangalore, India which was acquired from Stelis Biopharma Limited and was recorded as capital work in progress in earlier years. Consequently, Rs. 3,438 million has been capitalized as property, plant and equipment which has resulted in a higher depreciation of Rs. 70 million and Rs. 106 million during the quarter and half year ended September 30, 2025. 13. Events after the reporting period: The Company has made early and full redemption of the 107,000 unlisted, secured, rated, redeemable, Non-convertible Debentures (NCDs) aggregating to Rs. 10,700 million subsequent to approval by its Board of Directors in their meeting held on October 01, 2025. 14. Exceptional items: a. During the year ended March 31, 2025, the Company sold 8,000,000 equity shares of Rs. 10 each of Syngene in the open market. The gain arising from sale of aforesaid equity shares amounting to Rs. 6,075 million has been recorded as an exceptional item in the standalone financial results. Consequent tax impact of Rs. 261 million is included within tax expense for the year. The sale proceeds arising from such sale of aforesaid equity shares net of amount transferred to Non-Controlling Interest account, has been accounted in other equity in the consolidated financial results since there is no loss of control. b. During the year ended March 31, 2024, one of the subsidiaries of BBL recorded provision for inventory for a product due to its low demand and consequentially lower probability of liquidation under the head ‘Exceptional Item’. Subsequently, during the quarter ended September 30, 2024 and year ended March 31, 2025, BBL liquidated such inventory amounting to Rs. 260 million and Rs. 885 million, respectively. Hence, the related provision has been reversed and reflected as an exceptional item in the consolidated financial results. Consequential tax impact of Rs. 38 million and Rs. 147 million is included within tax expense for the respective period/ year. c. BBL had written off the unamortized portion of debt raise cost amounting to Rs. 1,216 million pertaining to acquisition debt pursuant to pre-payment of such debt. This has been recorded as an expense in the consolidated statement of profit and loss for the year ended March 31, 2025. Consequent tax impact of Rs. 304 million is included within tax expense for the year. d. During the year ended March 31, 2025, BBL had received Rs. 2,518 million towards working capital under the existing arrangements, which was recorded at fair value of Rs. 1,382 million having regard to the timing and profitability of recovery. The resulting difference of Rs. 1,136 million is recorded as a gain in the consolidated financial results. Consequential tax impact of Rs. 284 million is included within tax expense. e. During the quarter ended September 30, 2025, one of the subsidiaries of BBL has reached settlement on a litigation matter with one of its customers for a settlement amount of Rs. 291 million and disclosed under “exceptional item”. Pursuant to settlement, the amount disclosed under “other expenses” pertaining to previous quarter has been re-classified to “exceptional item”. The associated tax impact of Rs. 73 million is included in the tax expense for the period. f. During year ended March 31, 2025, one of the subsidiary of Biocon Pharma Limited (‘BPL’), pursuant to the uncertainty in commercialization of product in certain territories, recorded an impairment of the carrying value of the intangible asset amounting to Rs. 86 million. g. During the year ended March 31, 2025, the Group invested Rs. 75 million in the equity shares issued by Indian Foundation for Quality Management ('IFQM') a Company incorporated under section 8 of the Companies Act, 2013. As at March 31, 2025, the Group has fair valued such investment and has recorded fair value charge of Rs. 75 million. h. During the year ended March 31, 2025, Syngene received its final claim of Rs. 320 million from the insurance company for the loss of fixed assets in fire incident on December 12, 2016.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 30-09-2025
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 95,990.00
Capital work-in-progress 82,170.00
Investment property 5,200.00
Goodwill 0.00
Other intangible assets 5,310.00
Intangible assets under development 1,460.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 13,28,510.00
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets 2,010.00
Total non-current financial assets 13,30,520.00
Deferred tax assets (net) 0.00
Other non-current assets 21,200.00
Total non-current assets 15,41,850.00
2 Current assets
Inventories 93,440.00
Current financial asset
Current investments 84,790.00
Trade receivables, current 74,800.00
Cash and cash equivalents 1,68,440.00
Bank balance other than cash and cash equivalents 30.00
Loans, current 0.00
Other current financial assets 3,500.00
Total current financial assets 3,31,560.00
Current tax assets (net) 0.00
Other current assets 15,270.00
Total current assets 4,40,270.00
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 19,82,120.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 66,850.00
Other equity 15,31,460.00
Total equity attributable to owners of parent 15,98,310.00
Non controlling interest
Total equity 15,98,310.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 8,890.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities 370.00
Total non-current financial liabilities 9,260.00
Provisions, non-current 4,060.00
Deferred tax liabilities (net) 2,240.00
Deferred government grants, Non-current 0.00
Other non-current liabilities 5,950.00
Total non-current liabilities 21,510.00
Current liabilities
Current financial liabilities
Borrowings, current 2,45,010.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 11,390.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 73,060.00
Total Trade payable 84,450.00
Other current financial liabilities 14,850.00
Total current financial liabilities 3,44,310.00
Other current liabilities 3,540.00
Provisions, current 3,760.00
Current tax liabilities (Net) 10,690.00
Deferred government grants, Current 0.00
Total current liabilities 3,62,300.00
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 3,83,810.00
Total equity and liabilites 19,82,120.00
Disclosure of notes on assets and liabilities Textual Information(1)



Text Block

Textual Information(1) 1. The unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 in respect of Biocon Limited (‘the Company’) have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on November 11, 2025. The above results have been subjected to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified. 2. These financial results have been prepared in accordance with Indian Accounting Standards (‘Ind AS’) prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 3. The consolidated financial results include the financial results of the Company and its subsidiaries as follows: i. Syngene International Limited (‘’Syngene’’) ii. Biocon Biologics Limited (“BBL”) iii. Biocon Pharma Limited (“BPL”) iv. Biocon Academy v. Biocon SA vi. Biocon SDN. BHD vii. Biocon FZ LLC viii. Biocon Biologics International Limited (formerly known as Biocon Biologics UK Limited) ix. Biocon Pharma Inc. x. Biocon Biologics Healthcare Malaysia SDN. BHD xi. Biocon Pharma Ireland Limited xii. Biocon Pharma UK Limited xiii. Biocon Biosphere Limited xiv. Biocon Biologics Inc. xv. Biocon Biologics Do Brasil Ltda xvi. Biocon Biologics FZ-LLC xvii. Biocon Pharma Malta Limited xviii. Biocon Pharma Malta I Limited xix. Syngene USA Inc. xx. Syngene Manufacturing Solutions Limited xxi. Syngene Scientific Solutions Limited xxii. Biosimilar Collaborations Ireland Limited xxiii. Biocon Biologics UK PLC (formerly known as Biosimilars Newco Limited) xxiv. Biocon Biologics Canada Inc. xxv. Biocon Biologics Germany GmbH xxvi. Biocon Biologics France S.A.S xxvii. Biocon Biologics Spain, S.L. xxviii. Biocon Biologics Switzerland AG xxix. Biocon Biologics Belgium BV xxx. Biocon Biologics Finland OY xxxi. Biocon Generics Inc. xxxii. Biocon Biologics Morocco S.A.R.L.A.U xxxiii. Biocon Biologics Greece SINGLE MEMBER P.C xxxiv. Biocon Biologics South Africa (PTY) Ltd xxxv. Biocon Biologics (Thailand) Co. Ltd xxxvi. Biocon Biologics Philippines Inc xxxvii. Biocon Biologics Italy S.R.L xxxviii. Biocon Biologics Croatia LLC xxxix. Biocon Biologics Global PLC Biocon Limited and its subsidiaries are collectively referred to as ‘the Group’. In addition to the above, the consolidated financial results also include the financial results in respect of Biocon India Limited Employee Welfare Trust, Biocon Limited Employees Welfare Trust, Biocon Biologics Employees Welfare Trust and Syngene Employees Welfare Trust. The Company has also accounted for its share of interest in the joint venture i.e. NeoBiocon FZ-LLC (‘JV’) and share of investment in the associate i.e. Iatrica Inc., under the equity method. 4. During the quarter ended June 30, 2025, the Company raised funds by way of allotment of 136,363,635 Equity Shares of face value Rs. 5 each at a price of Rs. 330 per Equity Share under ‘Qualified Institutional Placement’ for an aggregate amount of Rs. 45,000 million, to meet certain financial commitments and / or debt obligations of the Company and its subsidiary, BBL and/ or for other purposes as mentioned in the Placement Document (‘PD’). Out of the above proceeds, on June 30, 2025, the Company acquired 1,125 outstanding Optionally Convertible Debentures (‘OCDs’) issued by BBL from Goldman Sachs India AIF Scheme- 1 and Goldman Sachs India Alternative Investment Trust AIF Scheme – 2 for an aggregate value of Rs. 16,980 million with a right to convert into equity shares or redeem at maturity. Further the company has issued a commitment letter effective July 1, 2025, committing to exercise its right to convert OCDs on maturity as per the terms of Subscription Agreement. Out of the above proceeds, during the quarter ended September 30, 2025, the Company has settled Commercial paper for an aggregate value of Rs. 5,988 million. 5. On April 23, 2025, the Board of Directors of Syngene recommended a final dividend of Rs. 1.25 per equity share of Rs. 10/-. This was approved by the shareholders of Syngene in the Annual General Meeting dated July 23, 2025, and has been distributed to the shareholders of Syngene during the quarter and half year ended September 30, 2025. 6. On May 08, 2025, the Board of Directors of the Company recommended a final dividend of Rs. 0.50 per equity share of Rs. 5/- each. This was approved by the shareholders of Company in the Annual General Meeting dated August 08, 2025, and has been distributed to the shareholders of the Company during the quarter and half year ended September 30, 2025. 7. In April 2024, BBL sold to Eris Lifesciences (‘Eris’) its business in relation to Metabolics, Oncology, and Critical Care products in India for a consideration of Rs. 12,420 million. Further, BBL signed a 10 year supply agreement with Eris. This resulted in a gain of Rs. 10,573 million after taking into account working capital and expenses incurred towards commercial collaboration and the same is disclosed under ‘’Other income” in the consolidated financial results for the year ended March 31, 2025. 8. Pursuant to amendment in The Finance Act, 2024, resulting in withdrawal of indexation benefit on Long-Term Capital Gain, the Company has written off Deferred Tax Asset created towards indexation benefit on Land amounting to Rs. 199 million. This is recorded under ‘Tax expense’ in the standalone and consolidated financial results for the quarter ended September 30, 2024 and year ended March 31, 2025. 9. The Group considers estimated shelf life of products, planned product discontinuances, price changes, ageing of inventory and introduction of competitive new products, to the extent each of these factors impact the Group’s business and markets, in determining the provision for slow moving, obsolete and other non-saleable inventory. Pursuant to the take-over of the Viatris's biosimilar business and completion of first anniversary since the exit from the transition service agreement, BBL re-assessed the provision for inventory of finished goods, raw material and semi-finished goods. This assessment resulted into a release of provision of Rs. 650 million in the year ended March 31, 2025 and the credit has been accounted for as a change in estimate within ‘Changes in inventories of traded goods, finished goods and work-in-progress’ and ‘Cost of materials consumed’ in the consolidated financial results. 10. During the year ended 31 March 2025, Syngene USA Inc. (wholly-owned subsidiary of Syngene) acquired biologics site in the USA fitted with multiple monoclonal antibody (mAbs) manufacturing lines from Emergent Manufacturing Operations Baltimore, LLC (a subsidiary of Emergent BioSolutions Inc.) and accounted for this transaction as an 'asset acquisition' under Ind AS 103. The costs incurred till March 31, 2025 eligible for capitalization were accumulated as Capital Work In Progress amounting to Rs. 2,981 million. An amount of Rs. 311 million has been capitalized as Land. These amounts include pre-transaction costs of Rs. 101 million. During the quarter and half year ended September 30 2025, additional pre-operating cost of Rs. 110 million and Rs. 165 million respectively, eligible for capitalisation has been accumulated under capital work in progress. 11. During the quarter and half year ended September 30, 2025, Syngene has written off Rs. 277 million as unrecoverable balances in receivables due to cumulative changes in foreign exchange rates. Consequent tax impact of Rs. 75 million is included within tax expense for the period. 12. During the quarter ended June 30, 2025, Syngene has been granted license for one of the drug substance production line and bonded warehouse license at biologics manufacturing facility, Bangalore, India which was acquired from Stelis Biopharma Limited and was recorded as capital work in progress in earlier years. Consequently, Rs. 3,438 million has been capitalized as property, plant and equipment which has resulted in a higher depreciation of Rs. 70 million and Rs. 106 million during the quarter and half year ended September 30, 2025. 13. Events after the reporting period: The Company has made early and full redemption of the 107,000 unlisted, secured, rated, redeemable, Non-convertible Debentures (NCDs) aggregating to Rs. 10,700 million subsequent to approval by its Board of Directors in their meeting held on October 01, 2025. 14. Exceptional items: a. During the year ended March 31, 2025, the Company sold 8,000,000 equity shares of Rs. 10 each of Syngene in the open market. The gain arising from sale of aforesaid equity shares amounting to Rs. 6,075 million has been recorded as an exceptional item in the standalone financial results. Consequent tax impact of Rs. 261 million is included within tax expense for the year. The sale proceeds arising from such sale of aforesaid equity shares net of amount transferred to Non-Controlling Interest account, has been accounted in other equity in the consolidated financial results since there is no loss of control. b. During the year ended March 31, 2024, one of the subsidiaries of BBL recorded provision for inventory for a product due to its low demand and consequentially lower probability of liquidation under the head ‘Exceptional Item’. Subsequently, during the quarter ended September 30, 2024 and year ended March 31, 2025, BBL liquidated such inventory amounting to Rs. 260 million and Rs. 885 million, respectively. Hence, the related provision has been reversed and reflected as an exceptional item in the consolidated financial results. Consequential tax impact of Rs. 38 million and Rs. 147 million is included within tax expense for the respective period/ year. c. BBL had written off the unamortized portion of debt raise cost amounting to Rs. 1,216 million pertaining to acquisition debt pursuant to pre-payment of such debt. This has been recorded as an expense in the consolidated statement of profit and loss for the year ended March 31, 2025. Consequent tax impact of Rs. 304 million is included within tax expense for the year. d. During the year ended March 31, 2025, BBL had received Rs. 2,518 million towards working capital under the existing arrangements, which was recorded at fair value of Rs. 1,382 million having regard to the timing and profitability of recovery. The resulting difference of Rs. 1,136 million is recorded as a gain in the consolidated financial results. Consequential tax impact of Rs. 284 million is included within tax expense. e. During the quarter ended September 30, 2025, one of the subsidiaries of BBL has reached settlement on a litigation matter with one of its customers for a settlement amount of Rs. 291 million and disclosed under “exceptional item”. Pursuant to settlement, the amount disclosed under “other expenses” pertaining to previous quarter has been re-classified to “exceptional item”. The associated tax impact of Rs. 73 million is included in the tax expense for the period. f. During year ended March 31, 2025, one of the subsidiary of Biocon Pharma Limited (‘BPL’), pursuant to the uncertainty in commercialization of product in certain territories, recorded an impairment of the carrying value of the intangible asset amounting to Rs. 86 million. g. During the year ended March 31, 2025, the Group invested Rs. 75 million in the equity shares issued by Indian Foundation for Quality Management ('IFQM') a Company incorporated under section 8 of the Companies Act, 2013. As at March 31, 2025, the Group has fair valued such investment and has recorded fair value charge of Rs. 75 million. h. During the year ended March 31, 2025, Syngene received its final claim of Rs. 320 million from the insurance company for the loss of fixed assets in fire incident on December 12, 2016.



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2025 01-04-2025
Date of end of reporting period 30-09-2025 30-09-2025
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit or loss 63000000 -27000000
Total Amount of items that will not be reclassified to profit and loss 630.00 (270.00)
2 Income tax relating to items that will not be reclassified to profit or loss 90.00 (100.00)
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified to profit or loss -61000000 -54000000
Total Amount of items that will be reclassified to profit and loss (610.00) (540.00)
4 Income tax relating to items that will be reclassified to profit or loss (160.00) (140.00)
5 Total Other comprehensive income 90.00 (570.00)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 30-09-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 7,810.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 12,340.00
Adjustments for decrease (increase) in inventories (9,810.00)
Adjustments for decrease (increase) in trade receivables, current 9,530.00
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 1,180.00
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 3,950.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 6,710.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 0.00
Adjustments for provisions, non-current (330.00)
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 2,640.00
Adjustments for interest income 0.00
Adjustments for share-based payments 1,940.00
Adjustments for fair value losses (gains) (12,310.00)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow (3,340.00)
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items (430.00)
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 6,790.00
Net cash flows from (used in) operations 14,600.00
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 1,100.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 13,500.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 1,69,800.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 0.00
Purchase of property, plant and equipment 10,800.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 80.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 9,060.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 2,640.00
Interest received 670.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (72,530.00)
Net cash flows from (used in) investing activities (2,58,960.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 4,50,000.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 490.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 44,160.00
Payments of lease liabilities 150.00
Dividends paid 6,680.00
Interest paid 4,300.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (6,360.00)
Net cash flows from (used in) financing activities 3,88,840.00
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 1,43,380.00
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 110.00
Net increase (decrease) in cash and cash equivalents 1,43,490.00
Cash and cash equivalents cash flow statement at beginning of period 24,950.00
Cash and cash equivalents cash flow statement at end of period 1,68,440.00





Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)

Amount in (Lakhs)

Mode of Fund Raising QIP
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 19-06-2025
Amount Raised 4,50,000.00
Report filed for Quarter ended 30-09-2025
Monitoring Agency Applicable
Monitoring Agency Name, if applicable India Ratings & Research Private Limited
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation Not Applicable
Comments of the Audit Committee after review Not Applicable
Comments of the auditors, if any Not Applicable
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Purchase of outstanding optionally convertible debentures issued by our Subsidiary, Biocon Biologics Limited from Goldman Sachs India AIF Scheme – 1 and Goldman Sachs India Alternative Investment Trust AIF Scheme – 2 Not Applicable 1,71,000.00 1,69,804.60 1,69,804.60 0.00 The Placement document states, if the actual utilization towards the objects is lower than the proposed deployment, such balance will be used for general corporate purposes. Accordingly, the lower utilization of INR 119.54 Mn towards object no. 1 on account of exchange rate fluctuation is added to General Corporate Purposes.
2 Repayment, pre-payment or redemption, in full or in part, of certain outstanding financial instruments issued by our Company, borrowings availed by our Company, and/or meeting other financial commitments of our Company Not Applicable 2,71,500.00 2,71,500.00 59,876.80 0.00
3 General Corporate Purposes Not Applicable 500.00 1,695.40 0.00 0.00 The Placement document states, if the actual utilization towards the objects is lower than the proposed deployment, such balance will be used for general corporate purposes. Accordingly, the lower utilization of INR 119.54 Mn towards object no. 1 on account of exchange rate fluctuation is added to General Corporate Purposes.
4 Issue related expenses Not Applicable 7,000.00 7,000.00 6,840.10 0.00


Signatory Details

Name of signatory Rajesh U. Shanoy
Designation of person Company Secretary and Compliance Officer
Place Bangaluru
Date 11-11-2025




Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Biocon Limited Biocon Biologics Limited Subsidiary Sale of goods or services 20,000.00 No remarks by the Audit Committee 8,203.00 0.00 0.00
2 Biocon Limited Biocon Biologics Limited Subsidiary Sale of goods or services 3,500.00 No remarks by the Audit Committee 1,536.00 0.00 0.00
3 Biocon Limited Biocon Biologics Limited Subsidiary Any other transaction ESOP cost recovery 2,300.00 No remarks by the Audit Committee 230.00 0.00 0.00
4 Biocon Limited Biocon Biologics Limited Subsidiary Any other transaction Other expenses recovery 2,498.00 No remarks by the Audit Committee 267.60 0.00 0.00
5 Biocon Limited Biocon Biologics Limited Subsidiary Sale of goods or services 1,250.00 No remarks by the Audit Committee 421.80 0.00 0.00
6 Biocon Limited Biocon Biologics Limited Subsidiary Sale of goods or services 4,700.00 No remarks by the Audit Committee 1,636.30 0.00 0.00
7 Biocon Limited Biocon Biologics Limited Subsidiary Any other transaction Expense for research and development services 3,004.20 No remarks by the Audit Committee 13.70 0.00 0.00
8 Biocon Limited Biocon SDN BHD Step down subsidiary Any other transaction ESOP cost recovery 500.00 No remarks by the Audit Committee 13.80 0.00 0.00
9 Biocon Limited Biocon SDN BHD Step down subsidiary Sale of goods or services 200.00 No remarks by the Audit Committee 28.20 0.00 0.00
10 Biocon Limited Biocon Biologics UK Limited Step down subsidiary Sale of goods or services 100.00 No remarks by the Audit Committee 12.10 0.00 0.00
11 Biocon Limited Biocon Biologics UK Limited Step down subsidiary Any other transaction ESOP cost recovery 100.00 No remarks by the Audit Committee 0.00 0.00 0.00
12 Biocon Limited Syngene International Limited Subsidiary Purchase of goods or services 200.00 No remarks by the Audit Committee 10.70 0.00 0.00
13 Biocon Limited Syngene International Limited Subsidiary Any other transaction Expenses reimbursement payable 100.00 No remarks by the Audit Committee 16.30 0.00 0.00
14 Biocon Limited Syngene International Limited Subsidiary Sale of goods or services 3,290.00 No remarks by the Audit Committee 1,323.80 0.00 0.00
15 Biocon Limited Syngene International Limited Subsidiary Sale of goods or services 3,160.00 No remarks by the Audit Committee 1,320.00 0.00 0.00
16 Biocon Limited Bicara Therapeutics Inc. Enterprise in which relative to a director of the Company is proprietor Sale of goods or services 2,000.00 No remarks by the Audit Committee 290.00 0.00 0.00
17 Biocon Limited Neo Biocon FZ LLC Associate Sale of goods or services 50.00 No remarks by the Audit Committee 0.00 0.00 0.00
18 Biocon Limited Neo Biocon FZ LLC Associate Purchase of goods or services 50.00 No remarks by the Audit Committee 0.00 0.00 0.00
19 Biocon Limited Immuneel Therapeutics Private Limited Enterprise in which a director of the Company is a member of board of directors Sale of goods or services 50.00 No remarks by the Audit Committee 0.00 0.00 0.00
20 Biocon Limited Biocon Foundation Trust in which a director is a trustee Any other transaction CSR Related activities 350.00 No remarks by the Audit Committee 141.00 0.00 0.00
21 Biocon Limited Jeeves Enterprise in which relative to a director of the Company is proprietor Purchase of goods or services 400.00 No remarks by the Audit Committee 102.10 0.00 0.00
22 Biocon Limited Mazumdar Shaw Medical Foundation Enterprise in which a director of the Company is a member of board of directors Purchase of goods or services 20.00 No remarks by the Audit Committee 0.00 0.00 0.00
23 Biocon Limited Biocon Pharma Limited Wholly owned subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 18,196.70 0.00 0.00
24 Biocon Limited Biocon Pharma Limited Wholly owned subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 90.30 0.00 0.00
25 Biocon Limited Biocon Pharma Limited Wholly owned subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 654.10 0.00 0.00
26 Biocon Limited Biocon Pharma Limited Wholly owned subsidiary Any other transaction ESOP cost recovery 0.00 No remarks by the Audit Committee 145.10 0.00 0.00
27 Biocon Limited Biocon Pharma Limited Wholly owned subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 189.60 0.00 0.00
28 Biocon Limited Biocon Pharma Limited Wholly owned subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 82.10 0.00 0.00
29 Biocon Limited Biocon Pharma Limited Wholly owned subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 18.70 0.00 0.00
30 Biocon Limited Biocon Pharma Limited Wholly owned subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 400.10 0.00 0.00
31 Biocon Limited Biocon Pharma Inc Wholly owned subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 1,632.50 0.00 0.00
32 Biocon Limited Biocon Pharma Inc Wholly owned subsidiary Any other transaction ESOP cost recovery 0.00 No remarks by the Audit Committee 194.30 0.00 0.00
33 Biocon Limited Biocon FZ LLC Wholly owned subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 191.80 0.00 0.00
34 Biocon Limited Biocon Biosphere Limited Wholly owned subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 2,212.70 0.00 0.00
35 Biocon Limited Biocon Biosphere Limited Wholly owned subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 223.30 0.00 0.00
36 Biocon Limited Biocon Biosphere Limited Wholly owned subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 590.00 0.00 0.00
37 Biocon Limited Biocon Biosphere Limited Wholly owned subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 4,730.00 0.00 0.00
38 Biocon Limited Biocon Biosphere Limited Wholly owned subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 680.00 0.00 0.00
39 Biocon Limited Biocon Biosphere Limited Wholly owned subsidiary Interest received 0.00 No remarks by the Audit Committee 267.10 0.00 0.00
40 Biocon Limited Biocon Biosphere Limited Wholly owned subsidiary Any other transaction ESOP cost recovery 0.00 No remarks by the Audit Committee 21.50 0.00 0.00
41 Biocon Limited Biocon Biosphere Limited Wholly owned subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 33.70 0.00 0.00
42 Biocon Limited Biocon Biosphere Limited Wholly owned subsidiary Loan 0.00 No remarks by the Audit Committee 9,240.00 0.00 0.00 Loan 7.20 On demand Unsecured Development of new manufacturing facility
43 Biocon Limited Biocon Biosphere Limited Wholly owned subsidiary Any other transaction Conversion of loan into OCRPS 0.00 No remarks by the Audit Committee 9,240.00 53,890.00 63,130.00
44 Biocon Limited Biocon Pharma Malta I Limited Wholly owned subsidiary Any other transaction ESOP cost recovery 0.00 No remarks by the Audit Committee 107.70 0.00 0.00
45 Biocon Limited Biocon Pharma Inc Wholly owned subsidiary Any other transaction Other expenses recovery 0.00 No remarks by the Audit Committee 1.30 0.00 0.00
46 Biocon Limited Biocon Biosphere Limited Wholly owned subsidiary Any other transaction Guarantee outstanding 0.00 No remarks by the Audit Committee 0.00 42,710.00 42,933.30
47 Biocon Pharma Limited Biocon Pharma UK Limited Wholly owned subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 430.00 0.00 0.00
48 Biocon Pharma Limited Biocon Pharma UK Limited Wholly owned subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 1,980.00 0.00 0.00
49 Biocon Pharma Limited Biocon Pharma Malta I Limited Wholly owned subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 950.00 0.00 0.00
50 Biocon Pharma Limited Biocon Pharma Malta I Limited Wholly owned subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 790.00 0.00 0.00
51 Biocon Biosphere Limited Biocon Biologics Limited Fellow subsidiary Purchase of goods or services 200.00 No remarks by the Audit Committee 140.00 0.00 0.00
52 Biocon Biosphere Limited Biocon Biologics Limited Fellow subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 150.00 70.00
53 Biocon Pharma Limited Biocon Biosphere Limited Fellow subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 40.00 1,120.00
54 Biocon Pharma Limited Biocon Biologics Limited Fellow subsidiary Purchase of goods or services 20,000.00 No remarks by the Audit Committee 2,200.00 0.00 0.00
55 Biocon Pharma Limited Biocon Biologics Limited Fellow subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 8,570.00 9,820.00
56 Biocon Pharma Limited Biocon Pharma Inc Wholly owned subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 14,970.00 0.00 0.00
57 Biocon Pharma Limited Biocon Generics Inc Wholly owned subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 170.00 0.00 0.00
58 Biocon Limited Biocon Generics Inc Wholly owned subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 1,438.60 0.00 0.00
59 Biocon Limited Biocon Generics Inc Wholly owned subsidiary Any other transaction ESOP cost recovery 0.00 No remarks by the Audit Committee 21.50 0.00 0.00
60 Biocon Limited Biocon Generics Inc Wholly owned subsidiary Any other transaction Charges for issue of corporate guarantee 0.00 No remarks by the Audit Committee 187.30 17,090.00 17,277.30
61 Biocon Limited Biocon Generics Inc Wholly owned subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 4,420.00 6,248.40
62 Biocon Limited Biocon Biologics Limited Subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 12,011.00 12,623.20
63 Biocon Limited Biocon Biologics Limited Subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 23,584.00 19,736.00
64 Biocon Limited Biocon SDN BHD Step down subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 2.50 10.00
65 Biocon Limited Biocon SDN BHD Step down subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 30.00 70.00
66 Biocon Limited Biocon Biologics UK Limited Step down subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
67 Biocon Limited Biocon Biologics UK Limited Step down subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 10.00 0.00
68 Biocon Limited Syngene International Limited Subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 210.00 40.00
69 Biocon Limited Syngene International Limited Subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 1,410.00 1,024.60
70 Biocon Limited Bicara Therapeutics Inc. Enterprise in which relative to a director of the Company is proprietor Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 120.00 121.00
71 Biocon Limited Biocon Foundation Trust in which a director is a trustee Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 320.00 180.00
72 Biocon Limited Biocon Pharma Limited Wholly owned subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 3,400.00 3,590.00
73 Biocon Limited Biocon Pharma Limited Wholly owned subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 13,550.00 3,190.00
74 Biocon Limited Biocon Pharma Inc Wholly owned subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 550.00 570.00
75 Biocon Limited Biocon Pharma Inc Wholly owned subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 530.00 2,430.00
76 Biocon Limited Biocon FZ LLC Wholly owned subsidiary Any other transaction ESOP cost recovery 0.00 No remarks by the Audit Committee 21.60 0.00 0.00
77 Biocon Limited Biocon FZ LLC Wholly owned subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 540.00 510.00
78 Biocon Limited Biocon FZ LLC Wholly owned subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
79 Biocon Limited Biocon Academy Wholly owned subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 130.00 130.00
80 Biocon Limited Biocon Biosphere Limited Wholly owned subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 2,630.00 7,476.30
81 Biocon Limited Biocon Biosphere Limited Wholly owned subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 4,320.00 7,880.00
82 Biocon Limited Biocon Pharma UK Limited Wholly owned subsidiary Any other transaction ESOP cost recovery 0.00 No remarks by the Audit Committee 21.50 0.00 0.00
83 Biocon Limited Biocon Pharma UK Limited Wholly owned subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 10.00 0.00
84 Biocon Limited Biocon Pharma Malta I Limited Wholly owned subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 40.00 46.30
85 Biocon Pharma Limited Biocon Pharma UK Limited Wholly owned subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 1,320.00 890.00
86 Biocon Pharma Limited Biocon Pharma UK Limited Wholly owned subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 1,780.00 2,290.00
87 Biocon Pharma Limited Biocon Pharma Ireland Limited Wholly owned subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 0.00 30.00
88 Biocon Pharma Limited Biocon Pharma Ireland Limited Wholly owned subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
89 Biocon Pharma Limited Biocon Pharma Malta Limited Wholly owned subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
90 Biocon Pharma Limited Biocon Pharma Malta Limited Wholly owned subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
91 Biocon Pharma Limited Biocon Pharma Malta I Limited Wholly owned subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 570.00 910.00
92 Biocon Pharma Limited Biocon Pharma Malta I Limited Wholly owned subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 970.00 1,570.00
93 Biocon Pharma Limited Biocon Pharma Inc Wholly owned subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 8,060.00 8,550.00
94 Biocon Pharma Limited Biocon Pharma Inc Wholly owned subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 48,370.00 25,480.00
95 Biocon Pharma Limited Biocon Foundation Trust in which a director is a trustee Any other transaction CSR 120.00 No remarks by the Audit Committee 70.00 0.00 0.00
96 Biocon Pharma Limited Biocon FZ LLC Fellow subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 50.00 50.00
97 Biocon Pharma Limited Biocon FZ LLC Fellow subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 20.00 20.00
98 Biocon Pharma Limited Biocon Generics Inc Wholly owned subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 440.00 422.30
99 Biocon Pharma UK Limited Biocon Pharma Ireland Limited Fellow subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
100 Biocon Pharma UK Limited Biocon Pharma Malta I Limited Fellow subsidiary Sale of goods or services 400.00 No remarks by the Audit Committee 142.70 0.00 0.00
101 Biocon Pharma UK Limited Biocon Pharma Malta I Limited Fellow subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 50.00 30.00
102 Biocon Pharma UK Limited Biocon Pharma Malta Limited Fellow subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
103 Biocon Pharma Malta I Limited Biocon SA Fellow subsidiary Loan 0.00 No remarks by the Audit Committee 0.00 440.00 440.00
104 Biocon Pharma Inc Biocon SA Fellow subsidiary Loan 12,996.00 No remarks by the Audit Committee 0.00 12,996.70 12,996.70
105 Biocon Pharma Inc Biocon SA Fellow subsidiary Interest paid 200.00 No remarks by the Audit Committee 96.80 0.00 0.00
106 Biocon Pharma Inc Biocon Generics Inc Fellow subsidiary Purchase of goods or services 15,000.00 No remarks by the Audit Committee 4,495.20 0.00 0.00
107 Biocon Pharma Inc Biocon Generics Inc Fellow subsidiary Any other transaction Trade and other payables 0.00 No remarks by the Audit Committee 0.00 1,220.00 960.00
108 Biocon Pharma Inc Biocon Generics Inc Fellow subsidiary Any other transaction Trade and other receivables 0.00 No remarks by the Audit Committee 0.00 160.00 230.00
109 Syngene International Limited Kiran Mazumdar Shaw Non-Executive Chairperson Any other transaction Sitting fees & Commission 95.00 No remarks by the Audit Committee 39.60 0.00 0.00
110 Syngene International Limited Professor Catherine Rosenberg Non-Executive Director Any other transaction Sitting fees & Commission 90.00 No remarks by the Audit Committee 45.80 0.00 0.00
111 Syngene International Limited Bicara Therapeutics Inc. Enterprise in which a Director of the Company is a member of the Board of Directors Sale of goods or services 9,370.00 No remarks by the Audit Committee 5,830.00 (1,380.00) (4,452.90)
112 Syngene International Limited Biocon Biologics Limited Fellow subsidiary Sale of goods or services 230.00 No remarks by the Audit Committee 48.30 990.00 1,371.10
113 Syngene International Limited Biocon Biologics UK Limited Fellow subsidiary Sale of goods or services 730.00 No remarks by the Audit Committee 237.90 260.00 49.90
114 Syngene International Limited Biocon Pharma Limited Fellow subsidiary Sale of goods or services 430.00 No remarks by the Audit Committee 4.60 150.00 3.40
115 Syngene International Limited Biocon SDN BHD Fellow subsidiary Sale of goods or services 70.00 No remarks by the Audit Committee 0.00 60.00 0.00
116 Syngene International Limited Biosimilar collaborations Ireland Fellow subsidiary Sale of goods or services 40.00 No remarks by the Audit Committee 0.00 20.00 0.00
117 Syngene International Limited BIOSIMILARS NEWCO LIMITED Fellow subsidiary Sale of goods or services 100.00 No remarks by the Audit Committee 53.60 0.00 1.40
118 Syngene International Limited Cage Therapeutics Incorporation Enterprise in which a Director of the Company is a member of the Board of Directors Sale of goods or services 57.20 No remarks by the Audit Committee 8.80 30.00 0.00
119 Syngene International Limited Immuneel Therapeutics Private Limited Enterprise in which a Director of the Company is a member of the Board of Directors Sale of goods or services 60.00 No remarks by the Audit Committee 43.20 20.00 78.70
120 Syngene International Limited Narayana Hrudayalaya Limited Enterprise in which a Director of the Company is a member of the Board of Directors Sale of goods or services 100.00 No remarks by the Audit Committee 0.00 0.00 0.00
121 Syngene International Limited Syngene Scientific solutions Ltd. Wholly owned subsidiary Sale of goods or services 403.70 No remarks by the Audit Committee 403.70 380.00 680.00
122 Syngene International Limited Therapoma Inc Enterprise in which a Director of the Company is a member of the Board of Directors Sale of goods or services 10.00 No remarks by the Audit Committee 3.90 0.00 2.50
123 Syngene International Limited Third Arc Bio Enterprise in which a Director of the Company has significant influence Sale of goods or services 4,000.00 No remarks by the Audit Committee 1,101.70 0.00 905.40
124 Syngene International Limited Biocon Biologics Limited Fellow subsidiary Sale of goods or services 3,700.00 No remarks by the Audit Committee 1,653.00 0.00 0.00
125 Syngene International Limited Syngene Manufacturing solutions Ltd. Wholly owned subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.50 0.00 0.00
126 Syngene International Limited Syngene Scientific solutions Ltd. Wholly owned subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.50 0.00 0.00
127 Syngene International Limited Biocon Biologics Limited Fellow subsidiary Sale of goods or services 1,000.00 No remarks by the Audit Committee 363.60 0.00 0.00
128 Syngene International Limited Syngene Scientific solutions Ltd. Wholly owned subsidiary Any other transaction Expenses reimbursement receivable 1,171.90 No remarks by the Audit Committee 1,171.90 0.00 0.00
129 Syngene International Limited Syngene USA Inc. Wholly owned subsidiary Any other transaction Expenses reimbursement receivable 643.10 No remarks by the Audit Committee 643.10 1,300.00 2,013.50
130 Syngene International Limited Therapoma Inc Enterprise in which a Director of the Company is a member of the Board of Directors Purchase of goods or services 120.00 No remarks by the Audit Committee 0.00 0.00 0.00
131 Syngene International Limited Biocon Biologics Limited Fellow subsidiary Any other transaction Expenses reimbursement receivable 150.00 No remarks by the Audit Committee 44.30 0.00 0.00
132 Syngene International Limited Syngene Scientific solutions Ltd. Wholly owned subsidiary Any other transaction Remittance of trade receivable realized 0.00 No remarks by the Audit Committee 0.00 0.00 (1,650.10)
133 Syngene International Limited Syngene Scientific solutions Ltd. Wholly owned subsidiary Purchase of goods or services 3,576.20 No remarks by the Audit Committee 3,576.20 0.00 0.00
134 Syngene International Limited Syngene Scientific solutions Ltd. Wholly owned subsidiary Purchase of goods or services 113.00 No remarks by the Audit Committee 113.00 0.00 0.00
135 Syngene International Limited Biocon Biologics Limited Fellow subsidiary Purchase of goods or services 1,590.00 No remarks by the Audit Committee 354.20 (380.00) (460.00)
136 Syngene International Limited Biocon Pharma Limited Fellow subsidiary Any other transaction Expenses reimbursement payable 100.00 No remarks by the Audit Committee 0.00 0.00 0.00
137 Syngene International Limited Immuneel Therapeutics Pvt Ltd. Enterprise in which a Director of the Company is a member of the Board of Directors Any other transaction Expenses reimbursement payable 100.00 No remarks by the Audit Committee 0.00 0.00 0.00
138 Syngene International Limited Biocon Biologics Limited Fellow subsidiary Purchase of goods or services 100.00 No remarks by the Audit Committee 0.00 0.00 0.00
139 Syngene International Limited Syngene Scientific solutions Ltd. Wholly owned subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 (1,340.00) 0.00
140 Syngene International Limited Biocon Academy Fellow subsidiary Any other transaction CSR 150.00 No remarks by the Audit Committee 119.50 0.00 (1.30)
141 Syngene International Limited Biocon Academy Fellow subsidiary Any other transaction Other 10.00 No remarks by the Audit Committee 10.50 0.00 0.00
142 Syngene International Limited Biocon Foundation Trust in which a director is a trustee Any other transaction CSR 1,100.00 No remarks by the Audit Committee 480.50 30.00 0.00
143 Syngene International Limited Syngene USA Inc. Wholly owned subsidiary Purchase of goods or services 5,377.30 No remarks by the Audit Committee 5,377.30 (480.00) (1,570.80)
144 Syngene International Limited Narayana Hrudayalaya Limited Enterprise in which a Director of the Company is a member of the Board of Directors Purchase of goods or services 50.00 No remarks by the Audit Committee 24.60 0.00 (0.50)
145 Syngene International Limited SOTC Travel Limited Enterprise in which a Director of the Company is a member of the Board of Directors of Holding Company Purchase of goods or services 600.00 No remarks by the Audit Committee 476.60 (50.00) (78.60)
146 Syngene International Limited Thomas Cook (India) Limited Enterprise in which a Director of the Company is a member of the Board of Directors Purchase of goods or services 100.00 No remarks by the Audit Committee 0.00 0.00 0.00
147 Syngene International Limited Jeeves Enterprise in which a member of the Promoter Group is a Partner Any other transaction Laundry service 50.00 No remarks by the Audit Committee 24.50 0.00 (1.40)
148 Biocon Biologics Limited Biocon SDN BHD Subsidiary Sale of goods or services 35,500.00 No remarks by the Audit Committee 4,405.60 (1,794.90) 224.30
149 Biocon Biologics Limited Biocon SDN BHD Subsidiary Purchase of goods or services 25,000.00 No remarks by the Audit Committee 6,269.20 0.00 0.00
150 Biocon Biologics Limited Biocon SDN BHD Subsidiary Any other transaction Guarantee given 0.00 No remarks by the Audit Committee 0.00 (8,543.00) (8,884.00)
151 Biocon Biologics Limited Biocon Biologics UK Limited Subsidiary Sale of goods or services 1,94,866.00 No remarks by the Audit Committee 0.00 75,405.60 30,061.60
152 Biocon Biologics Limited Biosimilar Collaborations Ireland Limited Subsidiary Sale of goods or services 2,12,966.00 No remarks by the Audit Committee 39,909.20 39,324.10 42,607.00
153 Biocon Biologics Limited Biocon Biologics Global Plc Subsidiary Sale of goods or services 2,500.00 No remarks by the Audit Committee 389.60 1,715.20 2,110.80
154 Biocon Biologics Limited Biocon Biologics Global Plc Subsidiary Any other transaction Guarantee given towards Senior Secured Notes isuued by BBGP, jointly and severally by BBL, BSDN, BCIL, BUK and BNCL 0.00 No remarks by the Audit Committee 0.00 (6,83,430.00) (7,81,792.00)
155 Biocon Biologics Limited Biosimilars Newco Limited Subsidiary Sale of goods or services 3,65,333.00 No remarks by the Audit Committee 1,03,244.50 47,070.00 62,061.30
156 Biocon Biologics Limited Biosimilars Newco Limited Subsidiary Purchase of goods or services 12,600.00 No remarks by the Audit Committee 644.30 0.00 0.00
157 Biocon Biologics Limited Biosimilars Newco Limited Subsidiary Any other transaction Guarantee given towards Debt obtained by BNCL, jointly/severally by BBL, BSDN, BCIL, BUK and BBGP 0.00 No remarks by the Audit Committee 0.00 (2,73,366.00) (2,84,288.00)
158 Biocon Biologics Limited Biocon Biologics Germany Subsidiary Sale of goods or services 5,300.00 No remarks by the Audit Committee 0.20 0.00 0.20
159 Biocon Biologics Limited Jeeves Enterprise in which relative to a director of the Company is proprietor Purchase of goods or services 1,000.00 No remarks by the Audit Committee 143.90 (3.50) (4.40)
160 Biocon Biologics Limited Narayana Hrudayalaya Limited Enterprise in which a director of the Company is a member of board of directors Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 8.90 8.90
161 Biocon Biologics Limited Biocon Academy Fellow subsidiary Purchase of goods or services 800.00 No remarks by the Audit Committee 200.00 128.90 379.20
162 Biocon Biologics Limited Biocon Foundation Fellow subsidiary Purchase of goods or services 1,000.00 No remarks by the Audit Committee 215.00 0.00 0.00
163 Biocon Biologics Limited Biocon Biologics Inc, US Subsidiary Sale of goods or services 2,500.00 No remarks by the Audit Committee 0.00 (309.10) (292.60)
164 Biocon Biologics Limited Biocon Biologics Inc, US Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
165 Biocon Biologics Limited Biocon Biologics Canada Inc Subsidiary Sale of goods or services 1,000.00 No remarks by the Audit Committee 0.00 25.00 25.00
166 Biocon Biologics Limited Biocon Biologics Philippines Subsidiary Sale of goods or services 0.00 No remarks by the Audit Committee 0.00 6.00 6.00
167 Biocon Biologics Limited Viatris Group Subsidiary Any other transaction Contingent consideration payable 0.00 No remarks by the Audit Committee 0.00 (89,700.00) (85,970.00)
168 Biocon Biologics UK Limited Biocon Biologics Inc, US Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 (0.30) (0.30)
169 Biocon Biologics UK Limited Biocon Biologics Brasil Ltda Subsidiary Purchase of goods or services 5,000.00 No remarks by the Audit Committee 0.00 106.90 1,187.90
170 Biocon Biologics UK Limited Biocon Biologics FZ-LLC, UAE Subsidiary Purchase of goods or services 5,000.00 No remarks by the Audit Committee 0.00 11.90 165.30
171 Biocon Biologics UK Limited Biocon Biologics Canada Inc Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 0.10 0.20
172 Biocon Biologics UK Limited Biocon Biologics (Thailand) Co., Ltd. Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 18.60 19.30
173 Biocon Biologics UK Limited Biocon Biologics Morocco S.R.L Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 793.90 825.60
174 Biocon Biologics UK Limited Biocon Biologics South Africa (Pty) Ltd. Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 142.00 147.60
175 Biocon Biologics UK Limited Biocon Biologics Philippines Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 255.60 269.00
176 Biocon Biologics UK Limited Biocon SDN BHD Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 (0.70) (0.70)
177 Biocon Biologics UK Limited Biocon Biologics Healthcare SDN BHD Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 3.60 4.40
178 Biocon Biologics UK Limited Biocon Biologics Global Plc Subsidiary Sale of goods or services 5,300.00 No remarks by the Audit Committee 375.30 326.90 724.90
179 Biocon Biologics UK Limited Biocon Biologics Global Plc Subsidiary Any other transaction Guarantee given towards Senior Secured Notes isuued by BBGP, jointly and severally by BBL, BSDN, BCIL, BUK and BNCL 0.00 No remarks by the Audit Committee 0.00 (6,83,430.00) (7,81,792.00)
180 Biocon Biologics UK Limited Biosimilar Collaborations Ireland Limited Subsidiary Sale of goods or services 33,500.00 No remarks by the Audit Committee 0.00 17,526.20 7,565.00
181 Biocon Biologics UK Limited Biosimilar Collaborations Ireland Limited Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
182 Biocon Biologics UK Limited Biosimilars Newco Limited Subsidiary Sale of goods or services 3,11,566.60 No remarks by the Audit Committee 3,116.60 34,428.00 25,452.60
183 Biocon Biologics UK Limited Biosimilars Newco Limited Subsidiary Purchase of goods or services 9,400.00 No remarks by the Audit Committee 0.00 0.00 0.00
184 Biocon Biologics UK Limited Biosimilars Newco Limited Subsidiary Any other transaction Guarantee given towards Debt obtained by BNCL, jointly/severally by BBL, BSDN, BCIL, BUK and BBGP 0.00 No remarks by the Audit Committee 0.00 (2,73,376.00) (2,84,288.00)
185 Biocon Biologics UK Limited Biocon Biologics Belgium BV Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 0.80 0.90
186 Biocon Biologics UK Limited Biocon Biologics Italy Subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 16.20 16.80
187 Biocon SDN BHD Biocon Biologics FZ-LLC, UAE Fellow subsidiary Purchase of goods or services 2,000.00 No remarks by the Audit Committee 57.20 (1,275.90) (58.90)
188 Biocon SDN BHD Biocon Biologics Inc, US Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 (1,076.50) 0.00
189 Biocon SDN BHD Biocon Biologics Healthcare SDN BHD Fellow subsidiary Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 20.10 22.00
190 Biocon SDN BHD Biosimilar Collaborations Ireland Limited Fellow subsidiary Sale of goods or services 23,100.00 No remarks by the Audit Committee 7,265.40 (6,738.60) (3,281.50)
191 Biocon SDN BHD Biosimilar Collaborations Ireland Limited Fellow subsidiary Purchase of goods or services 8,600.00 No remarks by the Audit Committee 98.80 0.00 0.00
192 Biocon SDN BHD Biocon Biologics Global Plc Fellow subsidiary Sale of goods or services 1,42,400.00 No remarks by the Audit Committee 34,681.30 2,907.40 (15,454.10)
193 Biocon SDN BHD Biocon Biologics Global Plc Fellow subsidiary Any other transaction Guarantee given towards Senior Secured Notes isuued by BBGP, jointly and severally by BBL, BSDN, BCIL, BUK and BNCL 0.00 No remarks by the Audit Committee 0.00 (6,83,430.00) (7,81,792.00)
194 Biocon SDN BHD Biosimilars Newco Limited Fellow subsidiary Sale of goods or services 1,50,700.00 No remarks by the Audit Committee 14,932.70 (25,722.80) (28,506.30)
195 Biocon SDN BHD Biosimilars Newco Limited Fellow subsidiary Any other transaction Guarantee given towards Debt obtained by BNCL, jointly/severally by BBL, BSDN, BCIL, BUK and BBGP 0.00 No remarks by the Audit Committee 0.00 (2,73,376.00) (2,84,288.00)
196 Biosimilars Newco Limited Biocon Biologics Canada Inc Fellow subsidiary Sale of goods or services 21,400.00 No remarks by the Audit Committee 1,948.20 (19,266.60) (23,408.00)
197 Biosimilars Newco Limited Biocon Biologics Inc, US Fellow subsidiary Sale of goods or services 3,27,500.00 No remarks by the Audit Committee 1,13,010.80 62,572.20 (23,363.50)
198 Biosimilars Newco Limited Biocon Biologics Inc, US Fellow subsidiary Purchase of goods or services 26,100.00 No remarks by the Audit Committee 1,058.10 0.00 0.00
199 Biosimilars Newco Limited Biocon Biologics Brasil Ltda Fellow subsidiary Purchase of goods or services 6,900.00 No remarks by the Audit Committee 1,862.20 0.00 (1,023.60)
200 Biosimilars Newco Limited Biocon Biologics FZ-LLC, UAE Fellow subsidiary Purchase of goods or services 6,400.00 No remarks by the Audit Committee 891.40 0.00 (686.30)
201 Biosimilars Newco Limited Biocon Biologics (Thailand) Co., Ltd. Fellow subsidiary Purchase of goods or services 1,000.00 No remarks by the Audit Committee 305.30 (290.70) (615.00)
202 Biosimilars Newco Limited Biocon Biologics Morocco S.R.L Fellow subsidiary Purchase of goods or services 3,200.00 No remarks by the Audit Committee 910.80 (1,050.40) (233.80)
203 Biosimilars Newco Limited Biocon Biologics South Africa (Pty) Ltd. Fellow subsidiary Purchase of goods or services 1,300.00 No remarks by the Audit Committee 172.30 (187.10) (243.80)
204 Biosimilars Newco Limited Biocon Biologics Philippines Fellow subsidiary Purchase of goods or services 1,500.00 No remarks by the Audit Committee 637.00 (425.30) (757.60)
205 Biosimilars Newco Limited Biocon Biologics Germany Fellow subsidiary Purchase of goods or services 4,800.00 No remarks by the Audit Committee 526.10 908.50 3,215.10
206 Biosimilars Newco Limited Biocon Biologics Germany Fellow subsidiary Sale of goods or services 14,600.00 No remarks by the Audit Committee 2,967.80 0.00 0.00
207 Biosimilars Newco Limited Biocon Biologics France Fellow subsidiary Sale of goods or services 18,400.00 No remarks by the Audit Committee 3,184.20 4,975.50 8,753.40
208 Biosimilars Newco Limited Biocon Biologics Spain Fellow subsidiary Sale of goods or services 6,700.00 No remarks by the Audit Committee 220.70 (899.10) (1,204.10)
209 Biosimilars Newco Limited Biocon Biologics Finland Fellow subsidiary Purchase of goods or services 2,300.00 No remarks by the Audit Committee 85.00 (247.40) (329.30)
210 Biosimilars Newco Limited Biocon Biologics Belgium BV Fellow subsidiary Purchase of goods or services 2,300.00 No remarks by the Audit Committee 93.90 (89.60) 10.80
211 Biosimilars Newco Limited Biocon Biologics Greece Fellow subsidiary Purchase of goods or services 2,700.00 No remarks by the Audit Committee 51.80 475.10 601.20
212 Biosimilars Newco Limited Biocon Biologics Greece Fellow subsidiary Sale of goods or services 5,500.00 No remarks by the Audit Committee 170.60 0.00 0.00
213 Biosimilars Newco Limited Biocon Biologics Swiss Fellow subsidiary Purchase of goods or services 4,400.00 No remarks by the Audit Committee 351.70 (37.80) (611.20)
214 Biosimilars Newco Limited Biocon Biologics Swiss Fellow subsidiary Sale of goods or services 4,700.00 No remarks by the Audit Committee 167.00 0.00 0.00
215 Biosimilars Newco Limited Biocon Biologics Italy Fellow subsidiary Purchase of goods or services 1,000.00 No remarks by the Audit Committee 829.20 27.50 (514.70)
216 Biosimilars Newco Limited Biocon Biologics Croatia Fellow subsidiary Purchase of goods or services 500.00 No remarks by the Audit Committee 366.50 (42.30) (45.40)
217 Biosimilars Newco Limited Biocon Biologics Global Plc Fellow subsidiary Purchase of goods or services 1,000.00 No remarks by the Audit Committee 0.00 5,445.20 14,936.50
218 Biosimilars Newco Limited Biocon Biologics Global Plc Fellow subsidiary Sale of goods or services 9,000.00 No remarks by the Audit Committee 2,114.90 0.00 0.00
219 Biosimilars Newco Limited Biocon Biologics Global Plc Fellow subsidiary Purchase of goods or services 60,000.00 No remarks by the Audit Committee 26,862.20 0.00 0.00
220 Biosimilars Newco Limited Biocon Biologics Global Plc Fellow subsidiary Any other transaction Guarantee given towards Senior Secured Notes isuued by BBGP, jointly and severally by BBL, BSDN, BCIL, BUK and BNCL 0.00 No remarks by the Audit Committee 0.00 (6,83,430.00) (7,81,792.00)
221 Biosimilar Collaborations Ireland Limited Biocon Biologics Inc, US Fellow subsidiary Sale of goods or services 13,200.00 No remarks by the Audit Committee 3,039.20 2,047.10 (3,993.80)
222 Biosimilar Collaborations Ireland Limited Biocon Biologics Inc, US Fellow subsidiary Purchase of goods or services 200.00 No remarks by the Audit Committee 0.00 0.00 0.00
223 Biosimilar Collaborations Ireland Limited Biocon Biologics Brasil Ltda Fellow subsidiary Sale of goods or services 15,300.00 No remarks by the Audit Committee 0.00 0.00 20.10
224 Biosimilar Collaborations Ireland Limited Biocon Biologics FZ-LLC, UAE Fellow subsidiary Purchase of goods or services 1,400.00 No remarks by the Audit Committee 0.00 3.80 4.00
225 Biosimilar Collaborations Ireland Limited Biocon Biologics Canada Inc Fellow subsidiary Sale of goods or services 18,100.00 No remarks by the Audit Committee 5,128.20 (961.00) 4,440.40
226 Biosimilar Collaborations Ireland Limited Biocon Biologics Canada Inc Fellow subsidiary Purchase of goods or services 500.00 No remarks by the Audit Committee 0.00 0.00 0.00
227 Biosimilar Collaborations Ireland Limited Biocon Biologics (Thailand) Co., Ltd. Fellow subsidiary Purchase of goods or services 1,000.00 No remarks by the Audit Committee 19.80 (22.30) (43.20)
228 Biosimilar Collaborations Ireland Limited Biocon Biologics Morocco S.R.L Fellow subsidiary Purchase of goods or services 3,200.00 No remarks by the Audit Committee 606.00 (173.80) (797.80)
229 Biosimilar Collaborations Ireland Limited Biocon Biologics Philippines Fellow subsidiary Sale of goods or services 5,900.00 No remarks by the Audit Committee 0.00 9.10 11.20
230 Biosimilar Collaborations Ireland Limited Biocon Biologics Germany Fellow subsidiary Sale of goods or services 1,57,333.30 No remarks by the Audit Committee 55,124.70 18,507.30 40,291.40
231 Biosimilar Collaborations Ireland Limited Biocon Biologics Germany Fellow subsidiary Purchase of goods or services 2,800.00 No remarks by the Audit Committee 0.00 0.00 0.00
232 Biosimilar Collaborations Ireland Limited Biocon Biologics France Fellow subsidiary Sale of goods or services 62,900.00 No remarks by the Audit Committee 22,479.50 4,589.60 (5,211.00)
233 Biosimilar Collaborations Ireland Limited Biocon Biologics Spain Fellow subsidiary Sale of goods or services 13,200.00 No remarks by the Audit Committee 2,276.20 4,368.20 4,548.20
234 Biosimilar Collaborations Ireland Limited Biocon Biologics Finland Fellow subsidiary Purchase of goods or services 2,300.00 No remarks by the Audit Committee 251.00 235.50 233.80
235 Biosimilar Collaborations Ireland Limited Biocon Biologics Belgium BV Fellow subsidiary Purchase of goods or services 3,800.00 No remarks by the Audit Committee 1,174.60 (237.20) (556.90)
236 Biosimilar Collaborations Ireland Limited Biocon Biologics Greece Fellow subsidiary Purchase of goods or services 2,700.00 No remarks by the Audit Committee 59.30 (2,259.40) (1,101.20)
237 Biosimilar Collaborations Ireland Limited Biocon Biologics Greece Fellow subsidiary Sale of goods or services 11,500.00 No remarks by the Audit Committee 5,471.30 0.00 0.00
238 Biosimilar Collaborations Ireland Limited Biocon Biologics Swiss Fellow subsidiary Sale of goods or services 5,800.00 No remarks by the Audit Committee 324.10 434.40 1,240.10
239 Biosimilar Collaborations Ireland Limited Biocon Biologics Italy Fellow subsidiary Purchase of goods or services 1,000.00 No remarks by the Audit Committee 0.00 160.00 (49.70)
240 Biosimilar Collaborations Ireland Limited Biocon Biologics Croatia Fellow subsidiary Purchase of goods or services 500.00 No remarks by the Audit Committee 257.30 31.20 (30.00)
241 Biosimilar Collaborations Ireland Limited Biocon Biologics Croatia Fellow subsidiary Sale of goods or services 7,400.00 No remarks by the Audit Committee 0.00 0.00 0.00
242 Biosimilar Collaborations Ireland Limited Biocon Biologics Global Plc Fellow subsidiary Sale of goods or services 1,000.00 No remarks by the Audit Committee 375.30 320.70 724.90
243 Biosimilar Collaborations Ireland Limited Biocon Biologics Global Plc Fellow subsidiary Any other transaction Guarantee given towards Senior Secured Notes isuued by BBGP, jointly and severally by BBL, BSDN, BCIL, BUK and BNCL 0.00 No remarks by the Audit Committee 0.00 (6,83,430.00) (7,81,792.00)
244 Biosimilar Collaborations Ireland Limited Biosimilars Newco Limited Fellow subsidiary Sale of goods or services 22,500.00 No remarks by the Audit Committee 2,467.00 0.00 0.00
245 Biosimilar Collaborations Ireland Limited Biosimilars Newco Limited Fellow subsidiary Purchase of goods or services 71,500.00 No remarks by the Audit Committee 32,444.60 (62,277.00) (1,55,421.80)
246 Biosimilar Collaborations Ireland Limited Biosimilars Newco Limited Fellow subsidiary Any other transaction Guarantee given towards Debt obtained by BNCL, jointly/severally by BBL, BSDN, BCIL, BUK and BBGP 0.00 No remarks by the Audit Committee 0.00 (2,73,376.00) (2,84,288.00)
247 Biosimilar Collaborations Ireland Limited Viatris Group Enterprise in which a director of the Company is a member of board of directors Purchase of goods or services 0.00 No remarks by the Audit Committee 0.00 0.00 0.00
248 Biocon Biologics Inc, US Biocon Biologics Global Plc Fellow subsidiary Purchase of goods or services 1,41,100.00 No remarks by the Audit Committee 35,957.40 (2,580.50) 4,838.80
249 Biocon Biologics France Viatris Sante S.A.S Enterprise in which a director of the Company is a member of board of directors Purchase of goods or services 2,000.00 No remarks by the Audit Committee 553.10 9.00 553.10
250 Biocon Biologics Global Plc Biosimilars Newco Limited Fellow subsidiary Loan 0.00 No remarks by the Audit Committee 0.00 6,76,885.80 7,03,904.20
251 Biocon Biologics Global Plc Biosimilars Newco Limited Fellow subsidiary Interest received 0.00 No remarks by the Audit Committee 0.00 23,957.60 26,753.30
252 Biocon Biologics Global Plc Biosimilars Newco Limited Fellow subsidiary Any other transaction Guarantee given towards Debt obtained by BNCL, jointly/severally by BBL, BSDN, BCIL, BUK and BBGP 0.00 No remarks by the Audit Committee 0.00 (2,73,376.00) (2,84,288.00)
253 Biocon Limited Kiran Mazumdar Shaw Key Management Personnel Remuneration 0.00 No remarks by the Audit Committee 271.90 0.00 0.00
254 Biocon Limited Ravi Mazumdar Non-Executive Director Any other transaction Sitting fees and commission 0.00 No remarks by the Audit Committee 39.10 0.00 0.00
Total value of transaction during the reporting period 6,58,145.20